The androgen receptor in bladder cancer
Journal
Nature reviews. Urology
Start Page
560
End Page
574
Date Issued
2023-09
Author(s)
Chen, Jinbo
Huang, Chi-Ping
Quan, Chao
Zu, Xiongbing
Ou, Zhenyu
Messing, Edward
Yeh, Shuyuan
Chang, Chawnshang
Abstract
Bladder cancer is the ninth most common cancer worldwide with a striking sex-based difference in incidence. Emerging evidence indicates that the androgen receptor (AR) might promote the development, progression and recurrence of bladder cancer, contributing to the observed sex differences. Targeting androgen-AR signalling has promise as potential therapy for bladder cancer and helps to suppress progression of this disease. In addition, the identification of a new membrane AR and AR-regulated non-coding RNAs has important implications for bladder cancer treatment. The success of human clinical trials of targeted-AR therapies will help in the development of improved treatments for patients with bladder cancer.
SDGs
Type
journal article